218 related articles for article (PubMed ID: 17547976)
41. Effect of neuromuscular activity on the response to botulinum toxin injections in spasmodic dysphonia.
Wong DL; Adams SG; Irish JC; Durkin LC; Hunt EJ; Charlton MP
J Otolaryngol; 1995 Aug; 24(4):209-16. PubMed ID: 8551532
[TBL] [Abstract][Full Text] [Related]
42. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section.
Sulica L; Blitzer A; Brin MF; Stewart CF
Ann Otol Rhinol Laryngol; 2003 Jun; 112(6):499-505. PubMed ID: 12834116
[TBL] [Abstract][Full Text] [Related]
43. Abductor paralysis after botox injection for adductor spasmodic dysphonia.
Venkatesan NN; Johns MM; Hapner ER; DelGaudio JM
Laryngoscope; 2010 Jun; 120(6):1177-80. PubMed ID: 20513036
[TBL] [Abstract][Full Text] [Related]
44. Safety of simultaneous bilateral botulinum toxin injections for abductor spasmodic dysphonia.
Stong BC; DelGaudio JM; Hapner ER; Johns MM
Arch Otolaryngol Head Neck Surg; 2005 Sep; 131(9):793-5. PubMed ID: 16172357
[TBL] [Abstract][Full Text] [Related]
45. Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection.
Warrick P; Dromey C; Irish JC; Durkin L; Pakiam A; Lang A
Laryngoscope; 2000 Aug; 110(8):1366-74. PubMed ID: 10942143
[TBL] [Abstract][Full Text] [Related]
46. Increased efficacy and decreased systemic-effects of botulinum toxin A injection after active or passive muscle manipulation.
Minamoto VB; Hulst JB; Lim M; Peace WJ; Bremner SN; Ward SR; Lieber RL
Dev Med Child Neurol; 2007 Dec; 49(12):907-14. PubMed ID: 18039237
[TBL] [Abstract][Full Text] [Related]
47. A survey of current practices of physicians who treat adductor spasmodic dysphonia in the U.S.
Chang CY; Chabot P; Walz CM
Ear Nose Throat J; 2009 May; 88(5):E18. PubMed ID: 19444777
[TBL] [Abstract][Full Text] [Related]
48. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients.
Elovic EP; Brashear A; Kaelin D; Liu J; Millis SR; Barron R; Turkel C
Arch Phys Med Rehabil; 2008 May; 89(5):799-806. PubMed ID: 18452724
[TBL] [Abstract][Full Text] [Related]
49. Transient erectile dysfunction associated with intramuscular injection of botulinum toxin type A.
Papadonikolakis AS; Vekris MD; Kostas JP; Korompilias AV; Soucacos PN
J South Orthop Assoc; 2002; 11(2):116-8. PubMed ID: 12741592
[TBL] [Abstract][Full Text] [Related]
50. Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia.
Adler CH; Bansberg SF; Krein-Jones K; Hentz JG
Mov Disord; 2004 Sep; 19(9):1075-9. PubMed ID: 15372600
[TBL] [Abstract][Full Text] [Related]
51. Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues.
Young DL; Halstead LA
J Voice; 2014 Sep; 28(5):614-7. PubMed ID: 24954039
[TBL] [Abstract][Full Text] [Related]
52. Onabotulinum toxin A dosage trends over time for adductor spasmodic dysphonia: A 15-year experience.
Tang CG; Novakovic D; Mor N; Blitzer A
Laryngoscope; 2016 Mar; 126(3):678-81. PubMed ID: 26308153
[TBL] [Abstract][Full Text] [Related]
53. Vocal outcome measures after bilateral posterior cricoarytenoid muscle botulinum toxin injections for abductor spasmodic dysphonia.
Klein AM; Stong BC; Wise J; DelGaudio JM; Hapner ER; Johns MM
Otolaryngol Head Neck Surg; 2008 Sep; 139(3):421-3. PubMed ID: 18722224
[TBL] [Abstract][Full Text] [Related]
54. Adductor spasmodic dysphonia: Botulinum toxin a injections or laser thyroarytenoid myoneurectomy? A comparison from the patient perspective.
Schuering JHC; Heijnen BJ; Sjögren EV; Langeveld APM
Laryngoscope; 2020 Mar; 130(3):741-746. PubMed ID: 31169922
[TBL] [Abstract][Full Text] [Related]
55. Low-dose subcutaneous injection of botulinum toxin type A for facial synkinesis and hyperlacrimation.
Ito H; Ito H; Nakano S; Kusaka H
Acta Neurol Scand; 2007 Apr; 115(4):271-4. PubMed ID: 17376126
[TBL] [Abstract][Full Text] [Related]
56. Spasmodic dysphonia follow-up with videolaryngoscopy and voice spectrography during treatment with botulinum toxin.
Esposito M; Dubbioso R; Apisa P; Allocca R; Santoro L; Cesari U
Neurol Sci; 2015 Sep; 36(9):1679-82. PubMed ID: 25966878
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of voice quality in adductor spasmodic dysphonia before and after botulinum toxin treatment.
Langeveld TP; van Rossum M; Houtman EH; Zwinderman AH; Briaire JJ; Baatenburg de Jong RJ
Ann Otol Rhinol Laryngol; 2001 Jul; 110(7 Pt 1):627-34. PubMed ID: 11465821
[TBL] [Abstract][Full Text] [Related]
58. Botulinum toxin treatment for spasmodic dysphonia: percutaneous versus transoral approach.
García Ruiz PJ; Cenjor Español C; Sanchez Bernardos V; Astarloa R; Sanabria J; García de Yébenes J
Clin Neuropharmacol; 1998; 21(3):196-8. PubMed ID: 9617512
[TBL] [Abstract][Full Text] [Related]
59. Botulinum toxin type A for treating voice tremor.
Adler CH; Bansberg SF; Hentz JG; Ramig LO; Buder EH; Witt K; Edwards BW; Krein-Jones K; Caviness JN
Arch Neurol; 2004 Sep; 61(9):1416-20. PubMed ID: 15364688
[TBL] [Abstract][Full Text] [Related]
60. Acoustic measures of symptoms in abductor spasmodic dysphonia.
Edgar JD; Sapienza CM; Bidus K; Ludlow CL
J Voice; 2001 Sep; 15(3):362-72. PubMed ID: 11575633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
